GlassScriptPhysician profile
Mamta Singh
NPI 1891031522
$965.37
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.43 · 2021: $397 · 2022: $474 · 2023: $52.51 · 2024: $22.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.14 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $182.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.69 | 2021-2022 | |
| Lilly USA, LLC | $91.21 | 2021-2022 | |
| Abbott Laboratories | $66.65 | 2021-2022 | |
| Glaxosmithkline, LLC. | $65.79 | 2021-2023 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $58.65 | 2021 | |
| Amarin Pharma, INC. | $50.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.70 | 2022 | |
| Pfizer INC. | $20.29 | 2023 | |
| Hologic Sales and Service, LLC | $19.43 | 2020 | |
| Genentech USA, INC. | $16.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.